HVC
ADMS

Healthcare Value Capital’s Adamas Pharmaceuticals ADMS Stock Holding History

Healthcare Value Capital’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-200,000
Closed -$578K – 25
2020
Q1 		$578K Hold
200,000
– – 0.97% 24
2019
Q4 		$758K Buy
+200,000
New +$957K 2.23% 14

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $4.21B AUM 44.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Healthcare Value Capital's ADMS Position: Q3 2021 in Review

Healthcare Value Capital held its Adamas Pharmaceuticals (ADMS) position steady in Q3 2021 at 100,000 shares worth $491K. The position accounts for 0.97% of the portfolio, ranked #22.

Healthcare Value Capital first reported a position in ADMS in Q1 2019 and has held it in 8 quarters since. The position peaked at $1.24M in Q2 2019. 63 funds tracked by Wall St. Rank hold ADMS as of Q3 2021.

  • Healthcare Value Capital held 100,000 shares of Adamas Pharmaceuticals worth $491K as of Q3 2021.
  • Healthcare Value Capital left its Adamas Pharmaceuticals share count unchanged in Q3 2021.
  • Adamas Pharmaceuticals made up 0.97% of Healthcare Value Capital's portfolio in Q3 2021, its #22 holding.
  • Healthcare Value Capital first reported a position in Adamas Pharmaceuticals in Q1 2019 and has held it in 8 quarters since.
  • Healthcare Value Capital's Adamas Pharmaceuticals position peaked at $1.24M in Q2 2019.
  • 63 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2021.

Based on Healthcare Value Capital's 13F filing for Q3 2021, filed 15 Nov 2021.